Dec 11 (Reuters) - Sanofi SA :
* TWO COMBINATION VACCINE CANDIDATES FOR PREVENTION OF INFLUENZA AND COVID-19 GRANTED FAST TRACK DESIGNATION IN THE US
* FDA GRANTS FAST TRACK DESIGNATION TO SANOFI COMBINATION VACCINE CANDIDATES
* SECOND CANDIDATE COMBINES FLUBLOK AND NOVAVAX COVID-19 VACCINE
* INITIATES PHASE 1/2 STUDIES FOR COMBINATION VACCINE CANDIDATES
* FIRST CANDIDATE COMBINES FLUZONE HIGH-DOSE AND NOVAVAX COVID-19 VACCINE
* NOVAVAX COVID-19 VACCINE SHOWS BETTER TOLERABILITY THAN MRNA VACCINES
Source text: Further company coverage:
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.